|
|
|
|
| LEADER |
01000caa a2200265 4500 |
| 001 |
OLC1989053270 |
| 003 |
DE-627 |
| 005 |
20230508075656.0 |
| 007 |
tu |
| 008 |
170207s2017 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a PQ20170206
|
| 035 |
|
|
|a (DE-627)OLC1989053270
|
| 035 |
|
|
|a (DE-599)GBVOLC1989053270
|
| 035 |
|
|
|a (PRQ)p882-7070a5a6eaf2ea15cdd436b7634058a045c887e4144619645d996e8a7a142fe80
|
| 035 |
|
|
|a (KEY)0171808820170000376000100004oligonucleotidetherapeuticsanewclassofcholesteroll
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
4 |
|a 610
|q DNB
|
| 084 |
|
|
|a XA 10000
|q AVZ
|2 rvk
|
| 084 |
|
|
|a 44.60
|2 bkl
|
| 084 |
|
|
|a 44.00
|2 bkl
|
| 100 |
0 |
|
|a Anastasia Khvorova
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Oligonucleotide Therapeutics -- A New Class of Cholesterol-Lowering Drugs
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 520 |
|
|
|a Another drug class may soon be added to cholesterol-lowering strategies: a chemically modified, small interfering RNA conjugated to the trivalent N-acetylgalactosamine. The siRNAs are oligonucleotide therapeutics, which destroy RNA before a protein is synthesized.
|
| 650 |
|
4 |
|a Immunoglobulins
|
| 650 |
|
4 |
|a Cholesterol
|
| 650 |
|
4 |
|a Statins
|
| 773 |
0 |
8 |
|i Enthalten in
|t The New England journal of medicine
|d Waltham, Mass. : MMS, 1928
|g 376(2017), 1, Seite 4
|w (DE-627)129495220
|w (DE-600)207154-X
|w (DE-576)014893169
|x 0028-4793
|7 nnns
|
| 773 |
1 |
8 |
|g volume:376
|g year:2017
|g number:1
|g pages:4
|
| 856 |
4 |
2 |
|u http://search.proquest.com/docview/1855897720
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_OLC
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a SSG-OLC-DE-84
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_105
|
| 912 |
|
|
|a GBV_ILN_168
|
| 912 |
|
|
|a GBV_ILN_183
|
| 912 |
|
|
|a GBV_ILN_290
|
| 912 |
|
|
|a GBV_ILN_2004
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2021
|
| 912 |
|
|
|a GBV_ILN_2219
|
| 912 |
|
|
|a GBV_ILN_2414
|
| 912 |
|
|
|a GBV_ILN_2424
|
| 912 |
|
|
|a GBV_ILN_4012
|
| 912 |
|
|
|a GBV_ILN_4112
|
| 912 |
|
|
|a GBV_ILN_4125
|
| 912 |
|
|
|a GBV_ILN_4126
|
| 912 |
|
|
|a GBV_ILN_4219
|
| 912 |
|
|
|a GBV_ILN_4256
|
| 912 |
|
|
|a GBV_ILN_4305
|
| 912 |
|
|
|a GBV_ILN_4306
|
| 912 |
|
|
|a GBV_ILN_4310
|
| 912 |
|
|
|a GBV_ILN_4315
|
| 912 |
|
|
|a GBV_ILN_4320
|
| 912 |
|
|
|a GBV_ILN_4323
|
| 936 |
r |
v |
|a XA 10000
|
| 936 |
b |
k |
|a 44.60
|q AVZ
|
| 936 |
b |
k |
|a 44.00
|q AVZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 376
|j 2017
|e 1
|h 4
|
